Magnesium and imidazole propionate.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Circulating levels of imidazole propionate (ImP), a microbial metabolite of histidine, were higher in participants with type 2 diabetes (T2D) compared to those without and also induced insulin resistance.

Who Took Part

The study group was 240 participants.

Among 68 participants (34 each in the treatment and placebo arms), the researchers measured plasma metabolites using the untargeted Metabolon's global Precision Metabolomics™ LC-MS platform.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Gastrointestinal Microbiome, Imidazoles and Magnesium.

The authors tagged it with the keywords Imidazole propionate, Microbial metabolite, Randomized controlled trial and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 240 participants.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Clinical nutrition ESPEN), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.